TABLE 2

Demographic characteristics of the study children (according-to-protocol cohorts for antibody persistence at 24 months [year 2], 36 months [year 3], and 60 months [year 5] after booster vaccination)

Parameter and time pointHib-MenC + PHiD-CVHib-MenC + 7vCRMMenC-CRMMenC-TT
naValuenValuenValuenValue
Age (mean ± SD) (mo)
    Year 214437.3 ± 1.214037.3 ± 1.314137.1 ± 1.214637.2 ± 1.2
    Year 313349.2 ± 1.513648.7 ± 1.213648.8 ± 1.313848.7 ± 1.1
    Year 513172.9 ± 1.013472.9 ± 1.212872.8 ± 1.013772.9 ± 1.1
Female (%)
    Year 214457.614050.714150.414644.5
    Year 313360.213652.213650.713843.5
    Year 513158.813450.712849.213746.0
European descent (%)
    Year 214495.114010014195.714698.6
    Year 313395.513699.313696.313897.8
    Year 513196.213499.312896.913797.8
  • a n, total number of children in the group.